(AXSM) Axsome Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05464T1043

Auvelity, Sunosi, Symbravo, AXS-05

AXSM EPS (Earnings per Share)

EPS (Earnings per Share) of AXSM over the last years for every Quarter: "2020-09-30": -0.58, "2020-12-31": -0.78, "2021-03-31": -0.78, "2021-06-30": -0.86, "2021-09-30": -0.93, "2021-12-31": -0.9, "2022-03-31": -1.03, "2022-06-30": -1.06, "2022-09-30": -1.07, "2022-12-31": -1.41, "2023-03-31": -0.26, "2023-06-30": -1.54, "2023-09-30": -1.32, "2023-12-31": -2.08, "2024-03-31": -1.44, "2024-06-30": -1.67, "2024-09-30": -1.3419, "2024-12-31": -1.54, "2025-03-31": -1.2157, "2025-06-30": -0.97,

AXSM Revenue

Revenue of AXSM over the last years for every Quarter: 2020-09-30: 0, 2020-12-31: 0, 2021-03-31: 0, 2021-06-30: 0, 2021-09-30: 0, 2021-12-31: 0, 2022-03-31: 0, 2022-06-30: 8.819786, 2022-09-30: 16.845792, 2022-12-31: 24.371528, 2023-03-31: 94.576, 2023-06-30: 46.7, 2023-09-30: 57.794, 2023-12-31: 71.53, 2024-03-31: 74.999, 2024-06-30: 87.166, 2024-09-30: 104.762, 2024-12-31: 118.766, 2025-03-31: 121.463, 2025-06-30: 150.042,

Description: AXSM Axsome Therapeutics

Axsome Therapeutics Inc (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The companys commercial product portfolio includes Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness, and Symbravo (AXS-07) for acute migraine treatment.

Key Performance Indicators (KPIs) to monitor Axsome Therapeutics include revenue growth from its commercial products, particularly Auvelity and Sunosi, as well as the progress of its pipeline assets, such as AXS-05, AXS-12, and AXS-14, through various stages of clinical trials. The companys ability to successfully navigate the FDA approval process and expand its product offerings will be crucial to its long-term success.

From a financial perspective, Axsome Therapeutics market capitalization stands at approximately $5.48 billion. The companys return on equity (ROE) is negative, indicating that it is currently unprofitable. As a result, traditional valuation metrics such as price-to-earnings (P/E) ratio are not applicable. Investors should focus on other metrics, such as revenue growth, cash burn rate, and pipeline progress, to gauge the companys potential for future growth.

The companys research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial for smoking cessation is a positive development, as it indicates a potential expansion of the drugs therapeutic applications. The progress of this trial, along with the companys other ongoing clinical trials, will be closely watched by investors and analysts.

From a technical analysis perspective, Axsome Therapeutics stock price is currently trading near its support level of $99.9. The stocks moving averages (SMA20, SMA50, and SMA200) are trending downward, indicating a bearish trend. Investors should monitor the stocks price action and adjust their strategies accordingly.

AXSM Stock Overview

Market Cap in USD 5,909m
Sub-Industry Pharmaceuticals
IPO / Inception 2015-11-19

AXSM Stock Ratings

Growth Rating 75.6%
Fundamental 27.3%
Dividend Rating -
Return 12m vs S&P 500 6.29%
Analyst Rating 4.74 of 5

AXSM Dividends

Currently no dividends paid

AXSM Growth Ratios

Growth Correlation 3m 71.3%
Growth Correlation 12m 63.6%
Growth Correlation 5y 71.4%
CAGR 5y 25.35%
CAGR/Max DD 3y 0.70
CAGR/Mean DD 3y 1.60
Sharpe Ratio 12m -0.44
Alpha 7.95
Beta 0.978
Volatility 39.40%
Current Volume 420.6k
Average Volume 20d 564.8k
Stop Loss 112.2 (-3.9%)
Signal -0.65

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (-246.9m TTM) > 0 and > 6% of Revenue (6% = 29.7m TTM)
FCFTA -0.20 (>2.0%) and ΔFCFTA 6.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 39.29% (prev 94.84%; Δ -55.55pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.19 (>3.0%) and CFO -120.6m > Net Income -246.9m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 1.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (49.4m) change vs 12m ago 3.93% (target <= -2.0% for YES)
Gross Margin 91.48% (prev 89.68%; Δ 1.80pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 83.34% (prev 53.17%; Δ 30.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -14.94 (EBITDA TTM -188.1m / Interest Expense TTM 13.2m) >= 6 (WARN >= 3)

Altman Z'' -8.78

(A) 0.30 = (Total Current Assets 536.6m - Total Current Liabilities 342.1m) / Total Assets 639.8m
(B) -1.92 = Retained Earnings (Balance) -1.23b / Total Assets 639.8m
warn (B) unusual magnitude: -1.92 — check mapping/units
(C) -0.33 = EBIT TTM -197.1m / Avg Total Assets 594.0m
(D) -2.17 = Book Value of Equity -1.23b / Total Liabilities 566.7m
Total Rating: -8.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 27.31

1. Piotroski 3.0pt = -2.0
2. FCF Yield -2.22% = -1.11
3. FCF Margin -25.99% = -7.50
4. Debt/Equity 2.57 = -0.11
5. Debt/Ebitda -1.00 = -2.50
6. ROIC - WACC -87.73% = -12.50
7. RoE -357.6% = -2.50
8. Rev. Trend 86.61% = 6.50
9. EPS Trend -19.21% = -0.96

What is the price of AXSM shares?

As of September 16, 2025, the stock is trading at USD 116.78 with a total of 420,600 shares traded.
Over the past week, the price has changed by -9.68%, over one month by +6.92%, over three months by +14.83% and over the past year by +26.37%.

Is Axsome Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Axsome Therapeutics (NASDAQ:AXSM) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 27.31 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AXSM is around 122.41 USD . This means that AXSM is currently overvalued and has a potential downside of 4.82%.

Is AXSM a buy, sell or hold?

Axsome Therapeutics has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy AXSM.
  • Strong Buy: 14
  • Buy: 5
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the AXSM price?

Issuer Target Up/Down from current
Wallstreet Target Price 176.8 51.4%
Analysts Target Price 176.8 51.4%
ValueRay Target Price 137.5 17.8%

Last update: 2025-09-16 04:31

AXSM Fundamental Data Overview

Market Cap USD = 5.91b (5.91b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 303.0m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 370.3704
P/S = 11.9373
P/B = 80.8667
Beta = 0.533
Revenue TTM = 495.0m USD
EBIT TTM = -197.1m USD
EBITDA TTM = -188.1m USD
Long Term Debt = 117.5m USD (from longTermDebt, last quarter)
Short Term Debt = 70.3m USD (from shortTermDebt, last quarter)
Debt = 187.9m USD (Calculated: Short Term 70.3m + Long Term 117.5m)
Net Debt = -87.7m USD (from netDebt column, last quarter)
Enterprise Value = 5.79b USD (5.91b + Debt 187.9m - CCE 303.0m)
Interest Coverage Ratio = -14.94 (Ebit TTM -197.1m / Interest Expense TTM 13.2m)
FCF Yield = -2.22% (FCF TTM -128.7m / Enterprise Value 5.79b)
FCF Margin = -25.99% (FCF TTM -128.7m / Revenue TTM 495.0m)
Net Margin = -49.88% (Net Income TTM -246.9m / Revenue TTM 495.0m)
Gross Margin = 91.48% ((Revenue TTM 495.0m - Cost of Revenue TTM 42.2m) / Revenue TTM)
Tobins Q-Ratio = -4.71 (set to none) (Enterprise Value 5.79b / Book Value Of Equity -1.23b)
Interest Expense / Debt = 0.98% (Interest Expense 1.83m / Debt 187.9m)
Taxrate = 21.0% (US default)
NOPAT = -197.1m (EBIT -197.1m, no tax applied on loss)
Current Ratio = 1.57 (Total Current Assets 536.6m / Total Current Liabilities 342.1m)
Debt / Equity = 2.57 (Debt 187.9m / last Quarter total Stockholder Equity 73.1m)
Debt / EBITDA = -1.00 (Net Debt -87.7m / EBITDA -188.1m)
Debt / FCF = -1.46 (Debt 187.9m / FCF TTM -128.7m)
Total Stockholder Equity = 69.0m (last 4 quarters mean)
RoA = -38.59% (Net Income -246.9m, Total Assets 639.8m )
RoE = -357.6% (Net Income TTM -246.9m / Total Stockholder Equity 69.0m)
RoCE = -105.6% (set to none) (Ebit -197.1m / (Equity 69.0m + L.T.Debt 117.5m))
RoIC = -78.38% (NOPAT -197.1m / Invested Capital 251.5m)
WACC = 9.35% (E(5.91b)/V(6.10b) * Re(9.62%)) + (D(187.9m)/V(6.10b) * Rd(0.98%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 1.56%
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -128.7m)
EPS Correlation: -19.21 | EPS CAGR: 3.49% | SUE: 0.29 | # QB: False
Revenue Correlation: 86.61 | Revenue CAGR: 121.5%

Additional Sources for AXSM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle